Group 1 - Huiyu Pharmaceutical's subsidiary received drug registration certificate for Carboxymethyl Sodium Injection, which is used for treating bleeding diseases in various medical fields [1] - Baihe Co., Ltd. announced a plan for a director to reduce holdings by up to 424,000 shares, representing 0.6625% of the total share capital [1] - Kingood Co., Ltd. received a notification from a global leading automaker for a wheel project, expected to start mass production in 2026 with a lifecycle of 10 years [1][2] Group 2 - Wanhua Chemical plans to repurchase shares worth between 300 million and 500 million yuan, with a maximum repurchase price of 99.36 yuan per share [2] - Warner Pharmaceutical's subsidiary received approval for Acetylcysteine raw material drug, primarily used for treating respiratory diseases [3] - ST Mingcheng plans to publicly transfer 45% equity of its subsidiary, aiming to optimize asset structure [4] Group 3 - Qixia Construction announced a plan to reduce up to 31.5 million shares, accounting for 3% of total share capital [5][6] - Zhejiang Rongtai intends to invest 20 million yuan to establish a wholly-owned subsidiary focused on intelligent robotics [7] - Yuandong Biological received drug registration for Chloral Hydrate Enema, used for sedation and seizure control in children [9] Group 4 - Jiemai Technology's subsidiary signed a strategic cooperation agreement with a solid-state battery company to produce high-safety composite conductive materials [10] - Xianju Pharmaceutical received drug registration for Progesterone Soft Capsules, used for treating functional disorders due to luteal deficiency [11] - Lanhua Kecai's subsidiary reported a temporary production halt, with the resumption date yet to be determined [13] Group 5 - Sinopharm Modern's subsidiary received drug registration for Tocilizumab Tablets, used for treating rheumatoid arthritis and other conditions [15] - Shanghai Bank announced the resignation of its vice president due to organizational adjustments [17] - Shanghai Pharmaceutical's Ephedrine Injection passed the consistency evaluation for generic drugs [19] Group 6 - Rundu Co., Ltd. received drug registration for Amlodipine and Olmesartan Tablets, aimed at treating hypertension [21] - Zhong'an Technology announced that 61 million shares held by its controlling shareholder will be auctioned [23] - Shanghai Washba plans to purchase patent assets and establish two subsidiaries focused on hydrogen energy and solid-state battery technologies [25] Group 7 - Nuo Cheng Jianhua's new drug Tafasitamab received approval for treating relapsed/refractory diffuse large B-cell lymphoma [26] - Benli Technology plans to use up to 200 million yuan of idle funds for cash management and financial investments [28] - Taiji Co., Ltd. intends to use 60 million yuan of idle funds to purchase financial products [29] Group 8 - Haishi Co. announced that its innovative drug Anreke Fen Injection received drug registration for treating postoperative pain [32] - Yulong Co. will have its stock delisted on May 27, 2025, following a decision by the Shanghai Stock Exchange [36] - Weifu High-Tech plans to establish a joint venture with Shanghai Baolong Automotive Technology [38] Group 9 - Xichang Electric Power expects a net profit reduction of approximately 5.4 million yuan due to adjustments in the time-of-use electricity pricing mechanism [39] - Alter signed a contract worth 6.8 billion yen for the development and procurement of large truck EV kits [41] - Zhonglian Heavy Industry plans to acquire controlling stakes in its financing leasing subsidiary through public bidding [42] Group 10 - Sanyou Medical's executive plans to reduce holdings by up to 1.44% of the company's shares [43] - Hangyang Co. plans to establish a subsidiary for large modular cryogenic equipment manufacturing with an estimated investment of 557 million yuan [44] - FAW Fuwi received a notification for a dashboard project from a well-known new energy brand, with total sales expected to reach 1.06 billion yuan [45]

持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 一、减持主体的基本情况 | | --- | | 股东名称 | 南京高科股份有限公司 | | | | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | □是 | □否 | | | 直接持股 5%以上股东 | √是 | □否 | | | 董事、监事和高级管理人员 | □是 | □否 | | | 其他： | | | | 持股数量 | 92,593,080股 | | | | 持股比例 | 8.818% | | | 1 | 证券代码：600533 | | | 证券简称：栖霞建设 | 公告编号：2025-017 | | --- | --- | --- | --- | --- | | 债券简称：22 | 栖建 | 01 | 债券代码：185951 | | | 债券简称：23 | 栖建 | 01 | 债券代码：240284 | | | 债券简称：24 | 栖建 | 02 | 债券代 ...

Group 1 - The core point of the article is that shareholder Nanjing Gaoke plans to reduce its stake in Qixia Construction by up to 3% of the total share capital within three months through centralized bidding and block trading [1] - The reduction will involve a maximum of 31.5 million shares, which are sourced from shares obtained prior to the IPO and those acquired through non-public offerings and profit distribution after the listing [1]

Core Viewpoint - The company is preparing for its 2024 annual meeting, focusing on independent audits, financial reports, and proposals for asset impairment provisions and guarantees for subsidiaries [3][4][5]. Meeting Agenda and Related Matters - The meeting is scheduled for May 29, 2025, at 14:30, in Nanjing, with a detailed agenda including the welcome address, independent director reports, and voting on various proposals [3][4]. - The meeting will address the independent audit report for 2024, the financial settlement report for 2023, and the proposal for the appointment of the accounting firm for 2024 [4][5]. Supervisory Board Work Report - The supervisory board held four meetings during the reporting period, reviewing the company's compliance with laws and regulations, and confirming that the board's operations were in accordance with the company's articles of association [4][5]. - The financial activities of the company were conducted in accordance with accounting standards, and the 2023 annual report accurately reflects the company's financial status [5][6]. Related Transactions - The company engaged in related transactions with its subsidiaries, ensuring that these transactions were conducted at market prices and did not harm the interests of shareholders [6][11]. - The total expected amount for related transactions in 2025 is projected to be 18,800 million yuan, with specific categories including construction materials and engineering services [8][9]. Asset Impairment Provisions - The company plans to recognize an asset impairment provision of 1,035.02 million yuan based on the results of impairment testing conducted on various assets as of December 31, 2024 [18][19]. - Specific provisions include 437.65 million yuan for the Nanjing Xingye Happy Garden and 276.92 million yuan for the Nanjing Fengqing Yuefu [18][19]. Guarantees for Subsidiaries - The company intends to provide guarantees for its subsidiaries, with a total authorization limit of 3.26 billion yuan for 2025, ensuring support for their operational needs [15][16]. - The guarantees are structured based on the subsidiaries' asset-liability ratios, with specific limits set for those above and below 70% [15][16]. Financial Data Overview - The financial data for 2024 indicates total assets and net assets for various subsidiaries, with some reporting losses, highlighting the need for careful financial management [10][17]. - The company's total external guarantees amount to 3.2986 billion yuan, representing 97.34% of the most recent audited net assets [18].

南京栖霞建设股份有限公司 2024 年年度股东大会 会议资料 二○二五年五月 2024 年年度股东大会会议资料 一、会议召集人：公司董事会 二、会议召开时间：2025 年 5 月 29 日 14:30 三、现场会议地点：南京市栖霞区仙林大道 99 号星叶广场 四、会议审议事项 1、2024 年度董事会工作报告 2、2024 年度监事会工作报告 3、2024 年度财务决算报告 4、2024 年度利润分配方案 5、关于支付 2024 年度会计师事务所报酬及 2025 年度续聘的议案 6、2024 年年度报告及年度报告摘要 7、关于 2025 年日常关联交易的议案 8、在授权范围内为控股子公司提供借款担保的议案 9、关于计提资产减值准备的议案 10、关于公司独立董事 2024 年度薪酬分配方案的议案 五、现场会议议程 （1）主持人致欢迎辞，并介绍会议有关事项； （2）听取 2024 年度独立董事述职报告； （3）宣读会议议案； （4）宣读会议表决办法，投票表决； （5）在计票的同时回答股东的提问； （6）宣布议案现场表决结果。 六、会议联系方式 联系地址：南京市仙林大道 99 号星叶广场公司证券投资部 联系电话：0 ...

Financial Performance - The company's total revenue is 2.118 billion, ranking 61 among disclosed peers, a decrease of 2.652 billion compared to the same period last year, representing a year-on-year decline of 55.60% [1] - The net profit attributable to shareholders is -0.938 billion, ranking 63 among disclosed peers, a decrease of 0.804 billion compared to the same period last year [1] - The net cash flow from operating activities is -0.355 billion, ranking 66 among disclosed peers, an increase of 0.705 billion compared to the same period last year [1] Financial Ratios - The latest debt-to-asset ratio is 85.45%, ranking 80 among disclosed peers, an increase of 3.34 percentage points compared to the same period last year [3] - The latest gross profit margin is 19.93%, ranking 47 among disclosed peers, an increase of 4.54 percentage points compared to the same period last year [3] - The latest return on equity (ROE) is -28.94%, ranking 71 among disclosed peers, a decrease of 25.71 percentage points compared to the same period last year [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share is -0.89, ranking 70 among disclosed peers, a decrease of 0.76 compared to the same period last year [3] - The latest total asset turnover ratio is 0.09 times, ranking 72 among disclosed peers, a decrease of 0.11 times compared to the same period last year, representing a year-on-year decline of 56.13% [3] - The latest inventory turnover ratio is 0.10 times, ranking 84 among disclosed peers, a decrease of 0.13 times compared to the same period last year, representing a year-on-year decline of 58.30% [3] Shareholder Structure - The number of shareholders is 43,400, with the top ten shareholders holding 539 million shares, accounting for 51.35% of the total share capital [3] - The largest shareholder is Nanjing Qixia Construction Group Co., Ltd., holding 34.37% [3] - Other notable shareholders include Nanjing Gaoke Co., Ltd. with 8.82% and Cao Huili with 3.93% [3]

二〇二五年四月二十八日 1 南京栖霞建设股份有限公司董事会 关于2024年度独立董事独立性自查情况的专项报告 根据《上市公司独立董事管理办法》、《上海证券交易所股票上市规则》、 《上海证券交易所上市公司自律监管指引第1号——规范运作》以及《公司章程》、 《独立董事工作制度》等有关规定和要求，南京栖霞建设股份有限公司（以下简 称"公司"）董事会经认真核查评估公司独立董事沈坤荣先生、杨东涛女士、张 秀莲女士、柳世平女士（已离任）相关任职经历及个人独立性自查情况报告，对 2024年度独立董事独立性自查情况发表专项意见如下： 除在上市公司担任独立董事外，沈坤荣先生、杨东涛女士、张秀莲女士、柳 世平女士（已离任）及其关系密切的家庭成员（配偶、父母、子女、兄弟姐妹、 兄弟姐妹的配偶、配偶的父母、配偶的兄弟姐妹、子女的配偶、子女配偶的父母 等）在其他企业担任职务方面、持有本公司股份方面以及重大业务往来等方面不 存在任何可能妨碍其进行独立客观判断的利害关系，亦不存在其他可能影响其独 立性的情况。综上，公司独立董事符合《上市公司独立董事管理办法》、《上海 证券交易所上市公司自律监管指引第1号——规范运作》等法律法规以及公司内 ...

证券代码：600533 证券简称：栖霞建设 公告编号：2025-016 南京栖霞建设股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2024年年度股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 5 月 29 日 14 点 30 分 召开地点：南京市仙林大道 99 号星叶广场 (五)网络投票的系统、起止日期和投票时间。 股东大会召开日期：2025年5月29日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 29 日 至2025 年 5 月 29 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9: ...

| 证券代码：600533 | | | 证券简称：栖霞建设 | 编号：临 2025-006 | | --- | --- | --- | --- | --- | | 债券简称：22 | 栖建 | 01 | 债券代码：185951 | | | 债券简称：23 | 栖建 | 01 | 债券代码：240284 | | | 债券简称：24 | 栖建 | 02 | 债券代码：240546 | | 南京栖霞建设股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 南京栖霞建设股份有限公司第九届监事会第二次会议通知于 2025 年 4 月 17 日发出，会议于 2025 年 4 月 28 日在南京市仙林大道 99 号星叶广场召开，监事 会成员 3 名，实际出席监事 3 名。会议符合《公司法》和《公司章程》的规定。 会议审议并通过了以下议案： 一、2024 年度监事会工作报告 表决结果：3 票同意，0 票反对，0 票弃权。 二、2024 年度财务决算报告 表决结果：3 票同意，0 票反对，0 票弃权。 三、对 2024 年年度报告 ...

第九届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | 证券代码：600533 | | | 证券简称：栖霞建设 | 编号：临 | 2025-005 | | --- | --- | --- | --- | --- | --- | | 债券简称：22 | 栖建 | 01 | 债券代码：185951 | | | | 债券简称：23 | 栖建 | 01 | 债券代码：240284 | | | | 债券简称：24 | 栖建 | 02 | 债券代码：240546 | | | 南京栖霞建设股份有限公司 南京栖霞建设股份有限公司第九届董事会第二次会议通知于 2025 年 4 月 17 日以电子传递方式发出，会议于 2025 年 4 月 28 日在南京市仙林大道 99 号星叶广 场召开，董事会成员 7 名，实际出席董事 7 名，会议符合《公司法》和《公司章程》 的规定。 会议审议并通过了以下议案： 一、2024 年度总裁工作报告 表决结果：7 票同意，0 票反对，0 票弃权。 二、2024 年度董事会工作报告 ...